Literature DB >> 29143926

Prolonging Time to Flare in Pediatric Atopic Dermatitis: A Randomized, Investigator-Blinded, Controlled, Multicenter Clinical Study of a Ceramide-Containing Moisturizer.

Lin Ma1, Ping Li2, Jianping Tang3, Yifeng Guo4, Chunping Shen5, Jing Chang3, Nabil Kerrouche6.   

Abstract

INTRODUCTION: Delaying or preventing flares is important in atopic dermatitis (AD) management. The objective of the study was to evaluate whether using a ceramide-containing moisturizer in addition to a body wash during latent AD can delay flares.
METHODS: This was a randomized, investigator-blinded, parallel-group, controlled study among Chinese children with a history of mild to moderate AD, within 1 week of successful treatment with a topical corticosteroid. Subjects were randomized to receive moisturizer twice daily and body wash once daily, or body wash alone once daily for 12 weeks. The primary efficacy endpoint was time to flare [necessitating medical therapy and/or Investigator Global Assessment (IGA) > 1 (at least mild AD)]. Other efficacy endpoints were AD characteristics and emollient effects. The patient-reported outcome comprised satisfaction at week 12. The safety endpoint was incidence of undesirable events.
RESULTS: A total of 64 subjects aged 2-12 years were randomized. Median time to flare was delayed by nearly 2 months for moisturizer/body wash compared to body wash alone (89 vs. 27 days, respectively). A significantly earlier onset of action in terms of fewer flares favoring moisturizer was found at week 4 (31 vs. 59%, respectively, p = 0.022), and after 12 weeks, fewer flares occurred (50 vs. 72%). At week 12 for flare-free subjects, nearly half in both groups had clear IGA, and an emollient effect in terms of less dryness or burning was more marked for moisturizer/body wash. Both products led to high patient satisfaction and were well tolerated.
CONCLUSION: A regimen incorporating a moisturizer plus body wash delayed AD flares by nearly 2 months compared to body wash alone, and yielded high patient satisfaction. FUNDING: Galderma R&D. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02589392.

Entities:  

Keywords:  Atopic dermatitis; Ceramide; Corticosteroid; Flare prevention; Moisturizer; Patient satisfaction

Mesh:

Substances:

Year:  2017        PMID: 29143926     DOI: 10.1007/s12325-017-0640-6

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

Review 1.  Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence.

Authors:  Adelaide A Hebert; Frank Rippke; Teresa M Weber; Noreen Heer Nicol
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 2.  Breaking the Itch-Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis.

Authors:  Ian P Harrison; Fabrizio Spada
Journal:  Medicines (Basel)       Date:  2019-07-18

3.  Distinct Skin Microbiota Imbalance and Responses to Clinical Treatment in Children With Atopic Dermatitis.

Authors:  Ying Liu; Shan Wang; Wenkui Dai; Yuan Liang; Chunping Shen; Yunzhu Li; Lei Jiao; Yawei Bian; Zhan Gao; Yinhu Li; Dongfang Li; Shuaicheng Li; Martin J Blaser; Yi-Wei Tang; Lin Ma
Journal:  Front Cell Infect Microbiol       Date:  2020-07-03       Impact factor: 5.293

4.  Cost Effectiveness of Emollients in the Prevention of Relapses in Atopic Dermatitis.

Authors:  Elise Cabout; Sebastien Eymere; Robert Launois; Flavia Aslanian; Charles Taïeb; Sophie Seité
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-21

Review 5.  Clinical significance of the water retention and barrier function-improving capabilities of ceramide-containing formulations: A qualitative review.

Authors:  Takeshi Kono; Yoshiki Miyachi; Makoto Kawashima
Journal:  J Dermatol       Date:  2021-10-01       Impact factor: 3.468

6.  Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis.

Authors:  Elise Cabout; Sébastien Eymere; Robert Launois; Sophie Séité; Véronique Delvigne; Charles Taïeb; Ziad Reguai
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.